演題抄録

ポスター

開催概要
開催回
第56回・2018年・横浜
 

当院における逐次療法の観点から検討したエンザルタミド・アビラテロンの臨床効果

演題番号 : P43-1

[筆頭演者]
演者)船越 大吾:1 
[共同演者]
大日方 大亮:1、鈴木 秋吾:1、橋本 翔:1、桜井 文紀:1、堀 祐太郎:1、吉澤 剛:1、松井 強:1、持田 淳一:1、山口 健哉:1、髙橋 悟:1

1:日本大学・板橋病院・泌尿器科

 

Despite resistance to androgen deprivation therapy (ADT), castration resistant prostate cancer (CRPC) still has high activity of androgen receptor (AR). Second generation AR directed drugs such as enzalutamide and abiraterone have significant effect on overall survival (OS) of CRPC. Recently, sequential therapy with enzalutamide and abiraterone was paid attention because it has possibility to maximize their drug ability for antiproliferation. Therefore, in this study, we retrospectively investigated the efficacy of sequential therapy using enzalutamide and abiraterone for CRPC.
Between Nov. 2014 and Jul. 2017, we investigated 33 cases sequentially treated with enzalutamide or abiraterone in Nihon University Itabashi hospital. Among them, xx cases were initially treated with abiraterone (A) then enzalutamide (E) (A-E) while xx cases (E) then (A) (E-A). The evaluated parameters for comparison of these two groups include patient characteristics, overall survival (OS), progression free survival (PFS) of whole treatment, and PSA best response rate within 3 months after initial agent. For the patient characteristics, we found no difference in mean age, TNM classification, ECOG performance status, and duration of ADT before CRPC. No difference was found in OS and PSA best response rate between the groups, whilst PFS was significantly prolonged in E-A group than A-E group (5.2 vs. 13.3 months, p=0.008, log-rank test).
In conclusion, E-A sequence might have more favorable efficacy in terms of PFS than A-E group.

キーワード

臓器別:前立腺・男性生殖器

手法別:内分泌・ホルモン療法

前へ戻る